

Parnell Living Science Welcomes New Hires

September 9, 2022 – Parnell Pharmaceuticals Holdings Ltd., a fully integrated, commercial-stage pharmaceutical company is proud to welcome two new employees to the U.S. headquarters facility located in the heart of the KC Animal Health Corridor in Overland Park, Kansas.

“We are thrilled to add these new team members to our organization. Their passion for customer service is a great match for our portfolio of animal health customers,” said Brad McCarthy, CEO of Parnell Living Science.

Andrew Hill, Financial Analyst



Andrew Hill has been appointed as the organization’s Financial Analyst, an integral part of the Finance Department. Andrew comes with a wealth of financial backgrounds, beginning with his work as a Mutual Fund Account Team Lead and as a financial analyst for a specialty insurance company. Andrew graduated from the University of Kansas with a degree in Economics.

Connect with [Andrew on LinkedIn here.](#)

Nicole Mathis, Financial Assistant



Nicole Mathis is Finance Assistant. Nicole handles customer inquiries, purchase orders and fulfillment. Nicole comes with almost 20 years of accounting experience. She has worked for a pharmaceutical company as well as an on-line learning provider. For Parnell, she handles the day-to-day activities of both the companion and the production sides of the business.

Connect with [Nicole on LinkedIn here.](#)

About Parnell

Parnell (OTC: PARNF) has a market-leading portfolio of products for companion, performance and production animals. Parnell is a technology and clinical science leader in dairy reproduction, marketing its proprietary brands [estroPLAN](#) and [GONAbreed](#) via its dedicated sales force and digital technology [mySYNCH](#) in the USA and Australia-New Zealand, and distributors in other markets. In companion animal, Parnell manufactures and markets its proprietary canine osteoarthritis brands [Glyde Mobility Chews for Dogs](#).